NCT05983029

Brief Summary

Our aim is to investigate whether a novel landmark, the groove between the buttocks or the intergluteal cleft, can facilitate the identification of the neuraxial midline in obstetric patients when compared to ultrasound as the reference standard for the determination of this midline

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
99

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 22, 2022

Completed
9 months until next milestone

First Posted

Study publicly available on registry

August 9, 2023

Completed
4 months until next milestone

Study Start

First participant enrolled

December 7, 2023

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2024

Completed
Last Updated

February 28, 2024

Status Verified

February 1, 2024

Enrollment Period

9 months

First QC Date

November 22, 2022

Last Update Submit

February 27, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Horizontal distance between intergluteal cleft and neuraxial midline

    One horizontal distance and hence one primary outcome

    12 months

Secondary Outcomes (3)

  • Difference in horizontal distance stratified by body mass index

    12 months

  • Difference in horizontal distance stratified by presence of pre-eclampsia

    12 months

  • Difference in horizontal distance stratified by presence of pregnancy induced hypertension

    12 months

Study Arms (1)

Study Group

Each patient will be requested to adopt a standardised upright position. First, two of the investigators will use a spirit level ruler and ink pen to agree upon and visibly mark the horizontal intercristal line on the back of the patient. Second, investigator B will leave the room, and investigator A will make a vertical mark with an ultraviolet pen denoting the intersection of the inferior aspect of the intergluteal cleft and the horizontal intercristal line. Third, investigator A will then leave the room, and investigator B will return to the room to make a vertical mark with an ink pen representing the intersection of the neuraxial midline, as established with the transverse spinous process view on ultrasound, and the horizontal intercristal line. After these two vertical marks have been made at the level of the intercristal line, the horizontal distance between them will be measured in mm by these same two investigators

Diagnostic Test: Intergluteal CleftDiagnostic Test: Neuraxial MidlineDiagnostic Test: Horizontal Distance between Vertical Markings

Interventions

Intergluteal CleftDIAGNOSTIC_TEST

Marking of intersection between inferior aspect of the intergluteal cleft and the horizontal intercristal line

Study Group
Neuraxial MidlineDIAGNOSTIC_TEST

Marking of intersection between the neuraxial midline, as established with the transverse spinous process view on ultrasound, and the horizontal intercristal line

Study Group

The horizontal distance between these two vertical marks will be measured at the level of the intercristal line

Study Group

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Pregnant patients

You may qualify if:

  • Female
  • years of age or older
  • Gestation of 37 weeks or above

You may not qualify if:

  • Acute or chronic confusional state
  • Allergy to ultrasound gel
  • Positive for COVID-19 and/or presence of symptoms consistent with SARS-Cov-2, such as anosmia, cough or fever
  • History of previous surgery to the spine
  • Scoliosis
  • Unable to speak and/or understand English

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Guy's Hospital, Great Maze Pond

London, SE1 9RT, United Kingdom

RECRUITING

Study Officials

  • Gill Arbane, BSc

    Guys' & St Thomas' NHS Foundation Trust

    STUDY CHAIR

Central Study Contacts

Neel Desai, FRCA

CONTACT

Marwa Salman, FRCA

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 22, 2022

First Posted

August 9, 2023

Study Start

December 7, 2023

Primary Completion

September 1, 2024

Study Completion

September 1, 2024

Last Updated

February 28, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

Locations